RGC-1502
/ ABVC BioPharma, Rgene Corp
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
August 09, 2024
A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
(clinicaltrials.gov)
- P2 | N=40 | Not yet recruiting | Sponsor: Rgene Corporation | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Apr 2026 ➔ Apr 2027
Metastases • Monotherapy • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
April 10, 2024
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
(GlobeNewswire)
- "ABVC BioPharma, Inc...announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc. (OncoX) for the Company's Oncology/Hematology pipeline(the 'Licensed Products')....Under the proposed agreement, ABVC would grant OncoX an exclusive global rights license to develop and commercialize the Licensed Products within the Field of Use. ABVC would also grant OncoX the right to sublicense to a third party, pre-agreed by ABVC....The terms discussed or agreed upon are conditional and not final until a formal Definitive Agreement is executed by all parties involved."
Licensing / partnership • Breast Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer
November 18, 2023
A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
(clinicaltrials.gov)
- P2 | N=40 | Not yet recruiting | Sponsor: Rgene Corporation | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: Apr 2025 ➔ Apr 2026
Metastases • Monotherapy • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
February 28, 2023
ABVC BioPharma Provides 2023 Pipeline Update
(GlobeNewswire)
- "While the company’s additional oncology medicines have yet to be determined, ABVC anticipates clinical studies for ABV-1519 for non-small cell lung cancer and ABV-1501 for triple negative breast cancer will be initiated in Q3 2023. The clinical study for ABV-1702 for myelodysplastic syndrome is expected to start in Q4 of 2023. In addition, ABVC intends to submit ABV-1703’s Phase II clinical trial IND to the Taiwan FDA after commencing clinical trials in the United States."
New P2 trial • New trial • Breast Cancer • Hematological Malignancies • Lung Cancer • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
February 15, 2023
A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
(clinicaltrials.gov)
- P2 | N=40 | Not yet recruiting | Sponsor: Rgene Corporation | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Oct 2024 ➔ Apr 2025
Metastases • Monotherapy • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
August 22, 2022
ABVC Provides Oncology Pipeline Updates
(GlobeNewswire)
- "ABVC BioPharma, Inc...today provided an update on its development of oncology medicines for the treatment pancreatic cancer (ABV-1703), non-small cell lung cancer (ABV-1519), triple negative breast cancer (ABV-1501) and myelodysplastic syndrome (ABV-1702). The Company expects to initiate the first Phase II clinical trials for ABV-1703 in the second quarter of 2023 by Dr. Andrew E. Hendifar at the Cedars-Sinai Medical Center in Los Angeles, California....While the sites and principal investigators for the Company’s additional oncology medicines have yet to be determined, ABVC anticipates clinical studies for ABV-1519 for non-small cell lung cancer and ABV-1501 for triple negative breast cancer will be initiated in Q3 2023. The clinical study for ABV-1702 for myelodysplastic syndrome is expected to start in Q4 of 2023. The Company plans to submit ABV-1703’s Phase II clinical trial IND to the Taiwan FDA after commencing clinical trials in the United States."
New P2 trial • New trial • Non-US regulatory • Breast Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer
June 21, 2022
ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation
(GlobeNewswire)
- "ABVC Biopharma, Inc...announced that it has expanded its co-development partnership with Rgene Corporation. BioKey...has entered into a Clinical Development Service Agreement with Rgene to guide three Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of pancreatic cancer and RGC 1503 for the treatment of colorectal cancer patients...Under the terms of the new Services Agreement, BioKey is eligible to receive payments totaling $3.0 million over a 3-year period with each payment amount to be determined by certain regulatory milestones obtained during the agreement period....BLEX 404, the new drug under clinical development covered by the service agreement...with breast cancer and myelodysplastic syndromes (MDS) patients."
Licensing / partnership • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor
1 to 7
Of
7
Go to page
1